These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37343365)

  • 1. Evaluation of fentanyl immunoassay test strips for rapid in-situ detection of fentanyl and fentanyl analogs in seized samples and alternative matrices.
    Norman C; Marland V; McKenzie C; Ménard H; Nic Daéid N
    Int J Drug Policy; 2023 Aug; 118():104102. PubMed ID: 37343365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a lateral flow immunoassay for the detection of the synthetic opioid fentanyl.
    Angelini DJ; Biggs TD; Maughan MN; Feasel MG; Sisco E; Sekowski JW
    Forensic Sci Int; 2019 Jul; 300():75-81. PubMed ID: 31078080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples.
    Park JN; Sherman SG; Sigmund V; Breaud A; Martin K; Clarke WA
    Drug Alcohol Depend; 2022 Nov; 240():109610. PubMed ID: 36115223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the limit of detection of Fourier-transform infrared spectroscopy and immunoassay strips for fentanyl in a real-world setting.
    McCrae K; Tobias S; Grant C; Lysyshyn M; Laing R; Wood E; Ti L
    Drug Alcohol Rev; 2020 Jan; 39(1):98-102. PubMed ID: 31746056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of two brands of fentanyl test strips with 251 synthetic opioids reveals "blind spots" in detection capabilities.
    Hayes KL; Lieberman M
    Harm Reduct J; 2023 Dec; 20(1):175. PubMed ID: 38057832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the sensitivity, stability, and cross-reactivity of commercial fentanyl immunoassay test strips.
    Rodriguez-Cruz SE
    J Forensic Sci; 2023 Sep; 68(5):1555-1569. PubMed ID: 37420315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing the test strips: laboratory performance of fentanyl test strips.
    Halifax JC; Lim L; Ciccarone D; Lynch KL
    Harm Reduct J; 2024 Jan; 21(1):14. PubMed ID: 38238757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitazene test strips: a laboratory evaluation.
    De Vrieze LM; Stove CP; Vandeputte MM
    Harm Reduct J; 2024 Aug; 21(1):159. PubMed ID: 39198843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and Sensitive Detection of Fentanyl and Its Analogs by a Novel Chemiluminescence Immunoassay.
    Zhao JY; Uddin M; Unsihuay D; Butler W; Xia TW; Xu JZ; Wang S; Sheng X; Jannetto PJ; Wang P; Xia X
    Clin Chem; 2024 Jul; 70(7):978-986. PubMed ID: 38757262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in fentanyl testing.
    Uljon S
    Adv Clin Chem; 2023; 116():1-30. PubMed ID: 37852717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America.
    Lieberman M; Badea A; Desnoyers C; Hayes K; Park JN
    Harm Reduct J; 2024 Jun; 21(1):115. PubMed ID: 38877522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of a Norfentanyl Immunoassay in Specimens with Low Concentrations of Fentanyl and/or Norfentanyl.
    Uljon S; Tolan NV; Mahowald GK; Khaliq T; Urwiller ED; Fernandes MD; Basu SS; Kang P; Erickson TB; Hayes BD; Chai PR; Melanson SEF
    J Appl Lab Med; 2024 Sep; 9(5):895-904. PubMed ID: 38656327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lot testing protocol for quality assurance of fentanyl test strips for harm reduction applications.
    Fernando H; Amate A; Hayes KL; Whitehead HD; Desnoyers C; Uzobuife E; Denchfield MS; Whitelatch B; Lieberman M
    Harm Reduct J; 2024 Aug; 21(1):152. PubMed ID: 39169393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips.
    Lockwood TE; Vervoordt A; Lieberman M
    Harm Reduct J; 2021 Mar; 18(1):30. PubMed ID: 33750405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of 30 Fentanyl Analogs by Commercial Immunoassay Kits.
    Wharton RE; Casbohm J; Hoffmaster R; Brewer BN; Finn MG; Johnson RC
    J Anal Toxicol; 2021 Feb; 45(2):111-116. PubMed ID: 33580693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of lateral flow immunoassays for the detection of fentanyl in seized drug samples and postmortem urine.
    Angelini DJ; Biggs TD; Prugh AM; Smith JA; Hanburger JA; Llano B; Avelar R; Ellis A; Lusk B; Malik Naanaa A; Sisco E; Sekowski JW
    J Forensic Sci; 2021 Mar; 66(2):758-765. PubMed ID: 33275295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding sensitivity and cross-reactivity of xylazine lateral flow immunoassay test strips for drug checking applications.
    Sisco E; Nestadt DF; Bloom MB; Schneider KE; Elkasabany RA; Rouhani S; Sherman SG
    Drug Test Anal; 2024 Sep; 16(9):942-947. PubMed ID: 38043944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an UPLC-MS/MS method for the analysis of 16 synthetic opioids in segmented hair, and evaluation of the polydrug history in fentanyl analogue users.
    Ramírez Fernández MDM; Wille SMR; Jankowski D; Hill V; Samyn N
    Forensic Sci Int; 2020 Feb; 307():110137. PubMed ID: 31927248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An LC-MS-MS Method for the Analysis of Carfentanil, 3-Methylfentanyl, 2-Furanyl Fentanyl, Acetyl Fentanyl, Fentanyl and Norfentanyl in Postmortem and Impaired-Driving Cases.
    Sofalvi S; Schueler HE; Lavins ES; Kaspar CK; Brooker IT; Mazzola CD; Dolinak D; Gilson TP; Perch S
    J Anal Toxicol; 2017 Jul; 41(6):473-483. PubMed ID: 28830122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples.
    Green TC; Park JN; Gilbert M; McKenzie M; Struth E; Lucas R; Clarke W; Sherman SG
    Int J Drug Policy; 2020 Mar; 77():102661. PubMed ID: 31951925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.